Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXI Avenue Therapeutics	$0.37 +44.8%	$0.25	$0.17 ▼ $3.93	$1.16M	-0.08	130,872 shs	32,282 shs
CFRX ContraFect	$0.05	$0.05	$0.04 ▼ $13.02	$535K	0.29	1.39 million shs	910,216 shs
OVID Ovid Therapeutics	$0.41 -3.3%	$0.31	$0.24 ▼ $1.47	$28.80M	0.13	447,637 shs	584,241 shs
TYME Tyme Technologies	$0.31	$0.30	$0.22 ▼ $1.14	$53.51M	0.93	1.01 million shs	2.68 million shs
VSTM Verastem	$4.68 -1.3%	$6.11	$2.10 ▼ $9.10	$257.44M	0.71	1.29 million shs	1.21 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXI Avenue Therapeutics	0.00%	+7.38%	+28.70%	+40.33%	-89.39%
CFRX ContraFect	0.00%	0.00%	0.00%	0.00%	0.00%
OVID Ovid Therapeutics	0.00%	+17.73%	+39.99%	+44.64%	-53.66%
TYME Tyme Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
VSTM Verastem	0.00%	-1.68%	-20.41%	+0.86%	+71.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXI Avenue Therapeutics	2.0357 of 5 stars	0.0	4.0	0.0	4.6	0.9	0.0	1.9
CFRX ContraFect	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	4.7282 of 5 stars	3.6	5.0	0.0	4.6	2.7	2.5	0.6
TYME Tyme Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	3.0968 of 5 stars	3.5	5.0	0.0	0.0	0.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXI Avenue Therapeutics	0.00	N/A	N/A	N/A
CFRX ContraFect	0.00	N/A	N/A	N/A
OVID Ovid Therapeutics	3.20	Buy	$3.13	671.60% Upside
TYME Tyme Technologies	0.00	N/A	N/A	N/A
VSTM Verastem	3.00	Buy	$13.38	185.79% Upside

Current Analyst Ratings Breakdown

Latest CFRX, OVID, TYME, VSTM, and ATXI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$16.00 ➝ $12.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
4/24/2025	OVID Ovid Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	$1.92 per share	N/A
CFRX ContraFect	N/A	N/A	N/A	N/A	($19.92) per share	N/A
OVID Ovid Therapeutics	$570K	50.53	N/A	N/A	$0.96 per share	0.42
TYME Tyme Technologies	N/A	N/A	N/A	N/A	$0.47 per share	N/A
VSTM Verastem	$10K	25,716.60	N/A	N/A	($0.65) per share	-7.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXI Avenue Therapeutics	-$10.38M	-$7.49	0.02	∞	N/A	N/A	-471.57%	-296.50%	8/7/2025 (Estimated)
CFRX ContraFect	-$65.15M	-$19.27	N/A	N/A	N/A	N/A	N/A	-138.70%	N/A
OVID Ovid Therapeutics	-$26.43M	-$0.35	N/A	N/A	N/A	-4,562.23%	-34.17%	-25.34%	8/12/2025 (Estimated)
TYME Tyme Technologies	-$23.63M	-$0.14	N/A	∞	N/A	N/A	-28.30%	-26.21%	N/A
VSTM Verastem	-$130.64M	-$3.20	N/A	N/A	N/A	N/A	-2,003.62%	-127.97%	8/6/2025 (Estimated)

Latest CFRX, OVID, TYME, VSTM, and ATXI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q1 2025	OVID Ovid Therapeutics	-$0.14	-$0.14	N/A	-$0.14	$0.03 million	$0.13 million
5/13/2025	Q1 2025	VSTM Verastem	-$0.72	-$0.96	-$0.24	-$0.96	$0.10 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A
CFRX ContraFect	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
TYME Tyme Technologies	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXI Avenue Therapeutics	N/A	2.70	2.70
CFRX ContraFect	N/A	0.53	0.53
OVID Ovid Therapeutics	0.22	4.93	4.93
TYME Tyme Technologies	N/A	14.06	14.06
VSTM Verastem	N/A	3.50	3.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXI Avenue Therapeutics	17.34%
CFRX ContraFect	7.85%
OVID Ovid Therapeutics	72.24%
TYME Tyme Technologies	16.69%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
ATXI Avenue Therapeutics	1.80%
CFRX ContraFect	0.62%
OVID Ovid Therapeutics	13.10%
TYME Tyme Technologies	16.90%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXI Avenue Therapeutics	4	3.18 million	2.02 million	Not Optionable
CFRX ContraFect	23	10.70 million	10.64 million	Not Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable
TYME Tyme Technologies	17	172.21 million	143.10 million	Optionable
VSTM Verastem	50	54.95 million	53.80 million	Optionable

CFRX, OVID, TYME, VSTM, and ATXI Headlines

Recent News About These Companies

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial ...

July 11 at 6:28 PM | gurufocus.com

Verastem (VSTM) Reports Promising Phase 2 Trial Results in Ovarian Cancer | VSTM Stock News

July 11 at 6:28 PM | gurufocus.com

Verastem stock rises after LGSOC treatment data published in medical journal

July 11 at 5:15 PM | in.investing.com

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

July 11 at 5:07 PM | businesswire.com

Verastem, Inc. (VSTM) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

Verastem KRAS-Mutant Ovarian Cancer Treatment Activity Affirmed in Investigator-Initiated Study

July 8, 2025 | precisionmedicineonline.comP

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 8, 2025 | businesswire.com

BTIG Remains a Buy on Verastem (VSTM)

July 4, 2025 | theglobeandmail.com

Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment

July 4, 2025 | tipranks.com

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

June 30, 2025 | businesswire.com

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from Brokerages

June 28, 2025 | marketbeat.com

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

June 26, 2025 | seekingalpha.com

FY2025 EPS Estimates for Verastem Cut by Cantor Fitzgerald

June 26, 2025 | marketbeat.com

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - Morningstar

June 26, 2025 | morningstar.comM

Royal Bank Of Canada Has Lowered Expectations for Verastem (NASDAQ:VSTM) Stock Price

June 25, 2025 | marketbeat.com

Insider Sell Alert: Daniel Calkins Sells Shares of Verastem Inc (VSTM)

June 24, 2025 | gurufocus.com

Verastem, Inc. (NASDAQ:VSTM) CFO Daniel Calkins Sells 4,110 Shares

June 24, 2025 | marketbeat.com

Dan Paterson Sells 17,808 Shares of Verastem, Inc. (NASDAQ:VSTM) Stock

June 24, 2025 | marketbeat.com

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

June 24, 2025 | businesswire.com

Verastem’s SWOT analysis: biotech stock poised for growth amid challenges

June 15, 2025 | investing.com

Verastem reports promising cancer drug trial results

June 3, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
By Jeffrey Neal Johnson | June 18, 2025
View Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
By Jeffrey Neal Johnson | June 22, 2025
View The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
SoundHound Rises as Short Sellers Exit and AI Demand Grows
By Thomas Hughes | July 9, 2025
View SoundHound Rises as Short Sellers Exit and AI Demand Grows
The Meteoric Rise of Rocket Lab: A Space Stock to Watch
By Ryan Hasson | July 11, 2025
View The Meteoric Rise of Rocket Lab: A Space Stock to Watch
Astera Labs: AI Infrastructure Play With Significant Growth Ahead
By Nathan Reiff | June 26, 2025
View Astera Labs: AI Infrastructure Play With Significant Growth Ahead

CFRX, OVID, TYME, VSTM, and ATXI Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

$0.36 +0.11 (+44.84%)

As of 07/11/2025 03:55 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

ContraFect NASDAQ:CFRX

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Ovid Therapeutics NASDAQ:OVID

$0.40 -0.01 (-3.34%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$0.41 +0.01 (+1.98%)

As of 07/11/2025 07:55 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Tyme Technologies NASDAQ:TYME

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

Verastem NASDAQ:VSTM

$4.68 -0.06 (-1.27%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$4.76 +0.08 (+1.71%)

As of 07/11/2025 07:56 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time